NLS Pharmaceutics AG

NASDAQ
NLSP
paper.types.company
Rentabilité sur six mois: -31.36%
Rendement en dividendes: 0%
Secteur: Healthcare

2.32 $

+0.24 $ +11.54%
0.1139 $
9.68 $

paper.min_max_per_year

Calendrier des promotions NLS Pharmaceutics AG

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise NLS Pharmaceutics AG

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD.

plus de détails
The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2021-01-29
ISIN
CH0523961370
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV -77.55 0
P/E 0 0
Efficacité
Nom Signification Grade
ROA -659.14 0
ROE 137.79 10
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.1385 10
Debt/Ratio 0.8847 9
Debt/Equity -1.21 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 174.32 10
Rentabilité EPS, % -36.1 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 2.08 $ 0 $ 0 $ 11.54 % 0 % 0 %
common.calendar.number_days.7d 1.95 $ 0 $ 0 $ 18.97 % 0 % 0 %
common.calendar.number_days.30d 1.53 $ 1.61 $ 2.32 $ 52.13 % 0 % 0 %
common.calendar.number_days.90d 1.82 $ 1.3 $ 2.32 $ 27.47 % 0 % 0 %
common.calendar.number_days.180d 3.38 $ 1.3 $ 2.72 $ -31.36 % 0 % 0 %
common.calendar.number_days.1y 0.1662 $ 0.1139 $ 9.68 $ 1295.91 % 0 % 0 %
common.calendar.number_days.3y 0.625 $ 0.1139 $ 9.68 $ 271.2 % 0 % 0 %
common.calendar.number_days.5y 0 $ 0.1139 $ 9.68 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.1139 $ 9.68 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 1.98 $ 1.3 $ 2.57 $ 17.17 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Alexander Zwyer M.B.A. CEO & Director 917k 1969 (56 années)
Dr. George Apostol M.D. Chief Medical Officer and Global Head of Research & Development 390k 1973 (52 année)
Dr. Eric Konofal M.D., Ph.D. Co-Founder & Chief Scientific Officer 179k 1967 (58 années)
Ms. Elena Thyen-Pighin CFO, Principal Accounting & Financial Officer and Head of Finance & Human Resources 61k 1972 (53 année)

Informations sur l'entreprise

Adresse: Switzerland, Zurich, The Circle 6 - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://nlspharma.com